<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">

<title>DIVAVACEHD Project</title>

<style>
body{
  font-family: Arial, sans-serif;
  background-color:#f6f7f8;
  margin:0;
  padding:40px 20px;
  line-height:1.6;
  color:#1f2933;
}

.contenedor{
  max-width:900px;
  margin:auto;
  background:#ffffff;
  padding:40px;
  border-radius:12px;
}

.centrado{ text-align:center; }
.espacio{ height:40px; }

.titulo{
  font-family: "Segoe UI", Arial, sans-serif;
  font-size:22px;
  max-width:750px;
  margin:30px auto;
}

.logos{
  max-width:600px;
  margin:20px auto;
  text-align:center;
}

.logos img{
  height:60px;
  margin:15px;
  vertical-align:middle;
}

/* --- Consortium: balanced grid --- */
.logos-grid{
  max-width:520px;              /* un poco más ancho */
  margin:25px auto;             /* menos aire vertical */
  display:grid;
  grid-template-columns: repeat(2, 1fr);
  gap:18px 28px;                /* logos más cerca entre sí */
  justify-items:center;
  align-items:center;
}

.logos-grid div{
  width:150px;                  /* logos más grandes */
  height:100px;
  display:flex;
  align-items:center;
  justify-content:center;
}

.logos-grid img{
  max-width:100%;
  max-height:100%;
  object-fit:contain;
}


/* --- Micro details --- */
.micro-linea{
  width:60px;
  height:2px;
  background:#e5e7eb;
  margin:20px auto;
}

.badge{
  display:inline-block;
  min-width:26px;
  height:26px;
  border-radius:50%;
  background:#eef1f4;
  color:#555;
  font-size:13px;
  line-height:26px;
  text-align:center;
  margin-right:8px;
}

/* --- FIX duplicated numbering --- */
ol{
  list-style:none;
  padding-left:0;
}

hr{
  border:none;
  border-top:1px solid #ccc;
  margin:40px 0;
}

.footer{
  font-size:13px;
  color:#666;
  text-align:center;
  line-height:1.5;
}
</style>
</head>

<body>

<div class="contenedor">

  <div class="centrado">
    <img src="css/images/logo-principal.png" style="height:65px;">
  </div>

  <br>

  <div class="centrado">
    <a href="index.html">ES</a> | <a href="en.html">EN</a>
  </div>

  <div class="micro-linea"></div>

  <div class="centrado">

    <p class="titulo"><strong>
      DEVELOPMENT OF A DIVA SUBUNIT VACCINE AGAINST EPIZOOTIC HEMORRHAGIC DISEASE (EHD) IN CATTLE PRODUCED USING CRISBIO® TECHNOLOGY
    </strong></p>

    <p><strong>Funded by CDTI</strong></p>

    <div class="logos">
      <img src="css/images/aei.png">
      <img src="css/images/cdti.png">
    </div>

    <div class="espacio"></div>

    <p><em>
      This project has been funded by CDTI and AEI, supported by the Spanish Ministry of Science and Innovation, within the framework of the State Plan for Scientific, Technical and Innovation Research (PEICTI), with the aim of promoting technological development, innovation and high-quality research.
    </em></p>

    <div class="logos-grid">
      <div><img src="css/images/bbglobal.png"></div>
      <div><img src="css/images/proalt.png"></div>
      <div><img src="css/images/algenex.png"></div>
      <div><img src="css/images/farmalan.png"></div>
    </div>

  </div>

  <hr>

  <h3>Objectives</h3>

  <p>
    <strong>The main objective</strong> of the project is to develop a safe and effective DIVA subunit vaccine against epizootic hemorrhagic disease in cattle (EHDV serotype 8). This vaccine aims to protect cattle and other susceptible species, significantly reducing mortality and morbidity caused by this disease.
  </p>

  <ol>
    <li><span class="badge">1</span><strong>Validation of Protection Results in Cattle:</strong> Confirmation of efficacy, optimal dose and immune response in bovines.</li>
    <li><span class="badge">2</span><strong>Development of the Industrial Antigen Production Process:</strong> Optimization and industrial scale-up of the antigen using CrisBio® technology.</li>
    <li><span class="badge">3</span><strong>Development of Analytical and Diagnostic Tools:</strong> Development of quality control tools and differential diagnosis between vaccinated and infected animals.</li>
    <li><span class="badge">4</span><strong>Structural and Formulation Studies:</strong> Structural characterization of the antigen and optimization of stable and effective formulations.</li>
    <li><span class="badge">5</span><strong>Production of Regulatory Banks and Batches:</strong> Production of banks and regulatory batches under GMP conditions.</li>
    <li><span class="badge">6</span><strong>Execution of Clinical Trials and Generation of the Regulatory Dossier:</strong> Clinical trials in cattle and preparation of the regulatory dossier for EMA.</li>
  </ol>

  <hr style="margin:50px 0 20px 0;">

  <div class="footer">
    <p>© 2026 DIVAVACEHD Consortium — Biogénesis Global S.L., Protein Alternatives S.L., Alternative Gene Expression S.L.U. and Laboratorios Farmalan S.A.</p>
    <p>Project funded by CDTI and AEI, with support from the Spanish Ministry of Science and Innovation.</p>
    <p>This website is for informational purposes only.</p>
  </div>

</div>

<script src="https://counter.websiteout.com/js/36/0/0/0"></script>

</body>
</html>
